GlobeNewswire Inc.T3·9h ago
PASG Passage Bio, Inc. Common Stock
XNAS
9.59
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
PASG
$9.59
—
Key stats
$9.59
- 52-Week Range
- $3.29 – $20.00
- YTD
- -17.96%
- Straddle Price
- $7.25
- P/C Vol Ratio
- 0.67
- Market Cap
- $0.0B
- Open
- $3.37
- Day Range
- $3.36 – $3.37
- Volume
- 1,634
- Prev Close
- $3.37
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.47 |
| Cost of Equity (CAPM) | 11.96% (VRP-adj) |
| WACC | 12.10% |
| Volatility Risk Premium | -98.7pp (IV − HV30), ERP adj -25bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -810.4% |
| Book / Price | 41.5% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $4.36 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $3.85 |
| Bollinger Width / SMA20 | 1032.4% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: AMGN, BIIB, EXEL, GILD, HALO, MRNA, NBIX, RGEN, RVMD, TECH
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$14.30
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 34.5× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 18.3× · 8 peers |
| Peer P/B | $14.30 | 100% | median 10.2× · 10 peers |
| Peer P/S | n/a | 0% | median 6.6× · 9 peers |
| Market Anchor (SMA50) | $4.36 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 24
- List Date
- 2020-02-28
- CIK
- 0001787297
- Next Earnings
- 2026-11-09 (After-Close)
- EPS Forecast
- ($2.43) (1 est.)
- Headquarters
- Philadelphia, PA
- Homepage
- https://www.passagebio.com
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -33.64% | -22.50% | -9.88% | 8.76% | -29.64% | -1.63% | -14.76% |
| Feb | -6.83% | -36.88% | -17.45% | 76.25% | -9.68% | -24.44% | -3.17% |
| Mar | -10.45% | -8.28% | -25.76% | -20.12% | -26.44% | -10.59% | -16.94% |
| Apr | 10.55% | -38.68% | -12.61% | -5.84% | -15.54% | -34.90% | -16.17% |
| May | -29.52% | -6.25% | -5.84% | -15.56% | 30.20% | 16.10% | -1.81% |
| Jun | 1.53% | 26.88% | -3.36% | -35.95% | -8.23% | -16.58% | -5.95% |
| Jul | -21.07% | -21.43% | -2.78% | 0.56% | -15.57% | -1.76% | -10.34% |
| Aug | -0.99% | 14.12% | -12.25% | -26.17% | 24.22% | -1.34% | -0.40% |
| Sep | -16.86% | -37.50% | -14.99% | 5.74% | 12.94% | 1.35% | -8.22% |
| Oct | -13.92% | -16.44% | -2.88% | -5.22% | -5.54% | -20.05%* | -10.67% |
| Nov | -22.28% | 0.00% | -2.00% | 79.54% | 20.63% | -- | 15.18% |
| Dec | -13.49% | 15.97% | 51.42% | -43.85% | 43.55% | -- | 10.72% |
| Total | -83.53% | -82.23% | -54.10% | -41.51% | -8.60% | -67.09% | -56.18% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $3.85
SMA 50: $4.36
SMA 200: $6.52
Current: $3.36
EMA 12: $3.64
EMA 26: $3.94
MACD: -0.3011 | Signal: -0.0293
BEARISH
ADX (14): 15.23
RANGE
+DI: 20.64
−DI: 16.18
Momentum Oscillators
RSI (14): 33.67
NEUTRAL
Stoch %K: 5.03
Stoch %D: 10.56
Williams %R: -98.85
Volume & Volatility
BB Upper: $4.61
BB Lower: $3.08
NEUTRAL
OBV: -1,259,966
Vol SMA 20: 19,073
Vol ROC: -97.86%
ATR: $0.31
True Range: $0.01
HV 20: 116.5%
HV 30: 98.7%
HV 60: 77.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall assessment: BEARISH (6/10)
Key drivers:
- High volatility, beta 2.33 vs SPY
- Recent earnings history shows mixed performance
- Options market signals bearish sentiment
Primary risks:
- High risk due to high volatility and beta
- Potential for significant price swings based on options activity
Investment thesis:
PASG is a highly volatile stock with a recent history of mixed earnings performance. The options market is pricing in a potential move higher, but the technical indicators suggest a bearish sentiment. Recent news headlines are not available, which may impact our analysis.
Recent news sentiment impact:
The lack of recent news headlines may be impacting our analysis, as we typically rely on news to inform our views on a stock's direction.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): BEARISH, Medium-term (1-3 months): NEUTRAL, Long-term (3-12 months): BULLISH
Support/Resistance Levels:
- Lower band: $5.89
- Middle line: $7.62
- Upper band: $9.35
Momentum Signals:
- RSI (14): 54.73 (neutral)
- MACD: 0.24 / Signal: 0.17 / Histogram: 0.07 (bullish)
Volume Analysis:
- Volume SMA 20: 43483.65
- On-Balance Volume (OBV): 4519712.20
- Volume Rate of Change: 28.61%
News & Sentiment Analysis
Recent Headlines Summary: No recent news available
Sentiment Assessment: NEUTRAL
Catalyst Identification: None identified based on lack of recent news
Market Narrative: The lack of recent news headlines may be impacting our analysis, but we can still analyze the options market sentiment.
Risk & Volatility Assessment
Risk Interpretation:
- Beta 2.33 indicates high risk relative to market
- Volatility regime is currently high, with a volatility rank of 64.1% (Medium)
Options Market Signals:
- IV Rank: 64.1% (Medium)
- Current IV: 1281.8%
- Expected Move: $7.35 (30 DTE), 7-DTE: $7.35
- Volume Flow: 105 calls vs 3 puts
- Open Interest: 458 calls vs 15 puts
- Put/Call Volume Ratio: 0.03 (Bullish sentiment)
- Put/Call OI Ratio: 0.03
Downside Protection:
- Support levels: $5.89, $7.62
- Risk management considerations: stop-loss levels and position sizing based on volatility
Market Context & Positioning
Sector Performance: Not applicable due to lack of sector information
Institutional Activity: Volume patterns suggesting institutional interest is low
Correlation Analysis:
- R-squared interpretation: 0.03 indicates a weak correlation with the market
Relative Valuation: PASG is trading within its historical range, but recent volatility may impact this analysis.
Key Levels & Action Items
Critical Price Levels:
- Support levels: $5.89, $7.62
- Resistance levels: $9.35
Breakout/Breakdown Levels:
- Breakout level: $9.35 (upper band)
- Breakdown level: $5.89 (lower band)
Time-Sensitive Catalysts: None identified based on lack of recent news
Risk Management:
- Stop-loss levels and position sizing considerations based on volatility.
Please note that this analysis is based on the available data, but the lack of recent news headlines may impact our views on the stock's direction.
Generated
News
All PASG news →
GlobeNewswire Inc.T3·6d ago
GlobeNewswire Inc.T3·12mo ago
GlobeNewswire Inc.T3·20mo ago
GlobeNewswire Inc.T3·20mo ago
GlobeNewswire Inc.T3·23mo ago
GlobeNewswire Inc.T3·26mo ago
GlobeNewswire Inc.T3·27mo ago
Zacks Investment ResearchT3·28mo ago
GlobeNewswire Inc.T3·29mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
9 of 11 under expected move
Avg Expected Move
277.72%
Avg Actual Move
6.38%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-08-05 | After-Close | 0.89% | 0.32% | 0.36x | Within |
| 2021-11-04 | After-Close | 0.83% | 7.05% | 8.49x | Exceeded |
| 2023-01-09 | After-Close | 3.10% | 8.15% | 2.63x | Exceeded |
| 2023-08-07 | After-Close | 173.12% | 2.04% | 0.01x | Within |
| 2024-08-08 | After-Close | 172.84% | 6.18% | 0.04x | Within |
| 2024-11-13 | After-Close | 123.13% | 1.41% | 0.01x | Within |
| 2025-01-10 | After-Close | 219.60% | 4.49% | 0.02x | Within |
| 2025-03-04 | After-Close | 898.07% | 10.53% | 0.01x | Within |
| 2025-05-13 | After-Close | 861.02% | 9.63% | 0.01x | Within |
| 2025-08-12 | After-Close | 471.43% | 13.73% | 0.03x | Within |
| 2025-11-10 | Pre-Market | 130.87% | 6.68% | 0.05x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
PASG Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $7.25
7-DTE Move: $7.25
Days to Exp: — (2025-12-19)
Options Flow
Call Volume: 6
Put Volume: 4
P/C Volume: 0.667
BULLISH
Call OI: 457
Put OI: 16
P/C OI: 0.035
Total OI: 473
ATM Options Pricing
ATM Call: $0.25
ATM Put: $7.00
Call %: 2.6%
Put %: 73.0%
Chain Summary
Chain Volume: 10
Chain OI: 473
Last Updated: 12/19/2025
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Dec 9 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Dec 9 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$7.25Dec 19
Beta Analysis
Risk Metrics
Beta: 2.7188
Alpha: -42.57%
Correlation: 0.3030
R-Squared: 9.2%
Stock Volatility: 114.4%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own PASG
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $234K | #2845 of 3138 | -64.2% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
PASG Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 3,193,310 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
PASG Insider Trading (Form 4)
Latest: 2026-06-29Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | Lynx1 Capital Management LP | 10%+ Owner | Buy (P) | +100,110 | $4.12 | $412.2K | EDGAR |
| 2026-05-21 | Sandip Kapadia | Director | Grant (A) | +10,539 opt | — | EDGAR | |
| 2026-05-21 | Dolan Sondhi | Director | Grant (A) | +10,539 opt | — | EDGAR | |
| 2026-05-21 | Athena Countouriotis | Director | Grant (A) | +10,539 opt | — | EDGAR | |
| 2026-05-21 | Thomas Richard Kassberg | Director | Grant (A) | +10,539 opt | — | EDGAR | |
| 2026-05-21 | Derrell Porter | Director | Grant (A) | +10,539 opt | — | EDGAR | |
| 2026-05-21 | Maxine Gowen | Director | Grant (A) | +10,539 opt | — | EDGAR | |
| 2026-03-18 | William Chou | PRESIDENT AND CEO | Grant (A) | +58,000 opt | — | EDGAR | |
| 2026-03-18 | Kathleen Borthwick | CFO | Grant (A) | +15,610 opt | — | EDGAR | |
| 2026-01-12 | William Chou | PRESIDENT AND CEO | Mixed | +5,924 | $18.44 | -$75.2K | EDGAR |
| 2026-01-12 | Kathleen Borthwick | CFO | Mixed | +2,938 | $18.44 | -$38.0K | EDGAR |
| 2025-12-29 | William Chou | PRESIDENT AND CEO | Grant (A) | +20,000 RSU | — | EDGAR | |
| 2025-12-29 | Kathleen Borthwick | CFO | Grant (A) | +10,000 RSU | — | EDGAR | |
| 2025-09-15 | Lynx1 Capital Management LP | 10%+ Owner | Buy (P) | +64,016 | $6.99 | $447.5K | EDGAR |
| 2025-07-24 | Lynx1 Capital Management LP | 10%+ Owner | Buy (P) | +257,696 | $5.70 | $1.47M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
PASG Insider Holdings
8 insiders · @ $3.36
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Lynx1 Capital Management LP | 10%+ Owner | 673,759 | $2.26M | $3.38M | 5 | 2026-06-29 |
| 2 | ORBIMED ADVISORS LLC | 10%+ Owner | 385,918 | $1.30M | $5.69M | 4 | 2024-12-06 |
| 3 | OrbiMed Capital GP VII LLC | 10%+ Owner | 313,980 | $1.05M | $17.76M | 13 | 2025-06-26 |
| 4 | William Chou | PRESIDENT AND CEO | 10,600 | $35.6K | -$75.2K | 7 | 2026-03-18 |
| 5 | Kathleen Borthwick | CFO | 5,402 | $18.1K | -$50.8K | 9 | 2026-03-18 |
| 6 | Edgar B. Cale | GC & CORPORATE SECRETARY | 3,090 | $10.4K | $21.6K | 12 | 2025-03-18 |
| 7 | Athena Countouriotis | Director | 945 | $3.2K | $309.9K | 9 | 2026-05-21 |
| 8 | Saqib Islam | Director | 250 | $840 | $90.0K | 7 | 2025-05-30 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
PASG Board & Officers
As of SEC filings through Jun 29, 2026Directors 6
- Athena Countouriotis · since Feb 27, 2020
- Sandip Kapadia · since Feb 27, 2020
- Derrell Porter · since May 27, 2021
- William Chou · since Oct 10, 2022
- Dolan Sondhi · since Jul 28, 2023
- Thomas Richard Kassberg · since Sep 10, 2024
Officers 2
- William Chou · President and CEO · listed since Apr 2023
- Kathleen Borthwick · CFO · listed since Mar 2024
10% owners 2
- Lynx1 Capital Management LP (entity) · since Aug 7, 2024
- Weston Nichols · since Aug 7, 2024
Changes in the last 10 years (59)
| Sep 16, 2025 | The company announced the departure of Saqib Islam from the board in an SEC filing |
| Jun 26, 2025 | Orbimed Advisors LLC reported in an SEC filing no longer being a 10% owner |
| Jun 26, 2025 | OrbiMed Capital GP VII LLC reported in an SEC filing no longer being a 10% owner |
| Sep 10, 2024 | Thomas Richard Kassberg became a director |
| Aug 7, 2024 | Weston Nichols became a 10% owner |
| Aug 7, 2024 | Lynx1 Capital Management LP became a 10% owner |
| Jul 26, 2024 | The company announced the departure of Mark S Forman as Chief Medical Officer in an SEC filing |
| Mar 19, 2024 | Kathleen Borthwick listed as CFO (previously SVP, Interim CFO) in SEC filings |
| Jul 28, 2023 | Kathleen Borthwick became SVP, Interim CFO |
| Jul 28, 2023 | Dolan Sondhi became a director |
| Jul 26, 2023 | The company announced the departure of Thomas Woiwode from the board in an SEC filing |
| Apr 5, 2023 | William Chou listed as President and CEO (previously Chief Executive Officer) in SEC filings |
| Nov 14, 2022 | Edgar B. Cale listed as GC & Corporate Secretary (previously Interim CEO, GC & Corp. Sec.) in SEC filings |
| Oct 10, 2022 | William Chou became a director |
| Oct 10, 2022 | William Chou became Chief Executive Officer |
| Jul 2, 2022 | Michael E. Kamarck became a director |
| Jun 1, 2022 | Edgar B. Cale listed as Interim CEO, GC & Corp. Sec. (previously GC and Corporate Secretary) in SEC filings |
| May 26, 2022 | The company announced the departure of Maxine Gowen from the board in an SEC filing |
| May 26, 2022 | The company announced the departure of Bruce A Goldsmith from the board in an SEC filing |
| May 26, 2022 | The company announced the departure of Bruce A Goldsmith as CEO and President in an SEC filing |
| Mar 30, 2022 | Mark S Forman became Chief Medical Officer |
| Mar 7, 2022 | The company announced the departure of Liam Ratcliffe from the board in an SEC filing |
| Oct 26, 2021 | The company announced the departure of Jill M. Quigley as Chief Operating Officer in an SEC filing |
| Aug 23, 2021 | Simona King became Chief Financial Officer |
| Jul 19, 2021 | Monika Maria Toernsen became Chief Commercial Officer |
| May 30, 2021 | Brian Burkavage became Controller |
| May 27, 2021 | Derrell Porter became a director |
| Mar 22, 2021 | Eliseo Oreste Salinas became Chief Res. & Develop Officer |
| Feb 18, 2021 | Maxine Gowen became a director |
| Feb 27, 2020 | Versant Ventures VI GP-GP, LLC became a 10% owner |
| Feb 27, 2020 | Versant Ventures VI GP, L.P. became a 10% owner |
| Feb 27, 2020 | Versant Venture Capital VI, L.P. became a 10% owner |
| Feb 27, 2020 | Versant Vantage I, L.P. became a 10% owner |
| Feb 27, 2020 | Versant Vantage I GP-GP, LLC became a 10% owner |
| Feb 27, 2020 | Versant Vantage I GP, L.P. became a 10% owner |
| Feb 27, 2020 | Thomas Woiwode became a director |
| Feb 27, 2020 | Thomas Woiwode became a 10% owner |
| Feb 27, 2020 | Tadataka Yamada became a director |
| Feb 27, 2020 | Stephen P Squinto became a director |
| Feb 27, 2020 | Stephen P Squinto became Head of Research and Dev |
| Feb 27, 2020 | Saqib Islam became a director |
| Feb 27, 2020 | Sandip Kapadia became a director |
| Feb 27, 2020 | Richard Steven Morris became Chief Financial Officer |
| Feb 27, 2020 | Patrick J Heron became a director |
| Feb 27, 2020 | Patrick J Heron became a 10% owner |
| Feb 27, 2020 | Orbimed Advisors LLC became a 10% owner |
| Feb 27, 2020 | OrbiMed Capital GP VII LLC became a 10% owner |
| Feb 27, 2020 | Liam Ratcliffe became a director |
| Feb 27, 2020 | Jill M. Quigley became Chief Operating Officer |
| Feb 27, 2020 | James N Topper became a 10% owner |
| Feb 27, 2020 | Gary Romano became Chief Medical Officer |
| Feb 27, 2020 | Frazier Life Sciences IX, L.P. became a 10% owner |
| Feb 27, 2020 | Fhmls Ix, L.p. became a 10% owner |
| Feb 27, 2020 | Fhmls Ix, L.l.c. became a 10% owner |
| Feb 27, 2020 | Edgar B. Cale became GC and Corporate Secretary |
| Feb 27, 2020 | Bruce A Goldsmith became a director |
| Feb 27, 2020 | Bruce A Goldsmith became CEO and President |
| Feb 27, 2020 | Athena Countouriotis became a director |
| Feb 27, 2020 | Alexandros Fotopoulos became Chief Technical Officer |
Not reported recently (23)
- Edgar B. Cale · Last reported as GC & Corporate Secretary in an SEC filing dated Mar 18, 2025
- Simona King · Last reported as Chief Financial Officer in an SEC filing dated Aug 1, 2023
- Alexandros Fotopoulos · Last reported as Chief Technical Officer in an SEC filing dated Jun 20, 2023
- Thomas Woiwode · Last reported as a 10% owner in an SEC filing dated May 26, 2023
- Michael E. Kamarck · Last reported as a director in an SEC filing dated May 26, 2023
- Monika Maria Toernsen · Last reported as Chief Commercial Officer in an SEC filing dated Nov 18, 2022
- Eliseo Oreste Salinas · Last reported as Chief Res. & Develop Officer in an SEC filing dated Feb 14, 2022
- Brian Burkavage · Last reported as Controller in an SEC filing dated Jun 9, 2021
- Tadataka Yamada · Last reported as a director in an SEC filing dated May 28, 2021
- Richard Steven Morris · Last reported as Chief Financial Officer in an SEC filing dated May 21, 2021
- Gary Romano · Last reported as Chief Medical Officer in an SEC filing dated Mar 17, 2021
- Versant Vantage I, L.P. · Last reported as a 10% owner in an SEC filing dated Mar 3, 2020
- Versant Venture Capital VI, L.P. · Last reported as a 10% owner in an SEC filing dated Mar 3, 2020
- Versant Ventures VI GP-GP, LLC · Last reported as a 10% owner in an SEC filing dated Mar 3, 2020
- Frazier Life Sciences IX, L.P. · Last reported as a 10% owner in an SEC filing dated Mar 3, 2020
- Versant Vantage I GP-GP, LLC · Last reported as a 10% owner in an SEC filing dated Mar 3, 2020
- Fhmls Ix, L.l.c. · Last reported as a 10% owner in an SEC filing dated Mar 3, 2020
- Versant Ventures VI GP, L.P. · Last reported as a 10% owner in an SEC filing dated Mar 3, 2020
- Versant Vantage I GP, L.P. · Last reported as a 10% owner in an SEC filing dated Mar 3, 2020
- James N Topper · Last reported as a 10% owner in an SEC filing dated Mar 3, 2020
- Fhmls Ix, L.p. · Last reported as a 10% owner in an SEC filing dated Mar 3, 2020
- Patrick J Heron · Last reported as a director in an SEC filing dated Mar 3, 2020
- Stephen P Squinto · Last reported as a director in an SEC filing dated Mar 2, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
PASG Proposed Insider Sales (Form 144)
Latest: 2026-01-09
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-01-09 | Chou William | Officer | 4,076 | $75.1K | 2026-01-09 | Maxim Group | — | EDGAR |
| 2025-07-21 | OrbiMed Private Investments VII, LP | Stockholder | 132,645 | $737.5K | 2025-07-21 | Themis Trading LLC | — | EDGAR |
| 2025-07-15 | OrbiMed Private Investments VII, LP | Stockholder | 53,293 | $361.9K | 2025-07-15 | Themis Trading LLC | — | EDGAR |
| 2025-07-07 | OrbiMed Private Investments VII, LP | Stockholder | 259,000 | $112.1K | 2025-07-07 | Themis Trading LLC | — | EDGAR |
| 2025-06-24 | OrbiMed Private Investments VII, LP | Stockholder | 1,076,120 | $378.4K | 2025-06-24 | Themis Trading LLC | — | EDGAR |
| 2025-04-15 | OrbiMed Private Investments VII, LP | Stockholder | 787,179 | $301.5K | 2025-04-15 | International Strategy & Investm… | — | EDGAR |
| 2025-01-06 | OrbiMed Private Investments VII, LP | Stockholder | 1,140,740 | $945.7K | 2025-01-06 | Themis Trading LLC | — | EDGAR |
| 2024-12-04 | OrbiMed Private Investments VII, LP | Stockholder | 2,985,518 | $2.66M | 2024-12-04 | Themis Trading LLC | — | EDGAR |
| 2024-12-04 | Worldwide Healthcare Trust PLC | Stockholder | 2,028,307 | $1.81M | 2024-12-04 | Themis Trading LLC | — | EDGAR |
| 2024-09-16 | Worldwide Healthcare Trust PLC | Owner | 241,328 | $194.8K | 2024-09-16 | Themis Trading LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
2 ETFs hold PASG
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-11.32
TTM Revenue
—
TTM Net Income
$-36.11M
TTM Op. Cash Flow
$-33.50M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-7.82M | $-2.44 | $-9.18M |
| Q1 '26 | 2026-03-31 | — | $-7.56M | $-2.36 | $-12.99M |
| Q4 '25 | 2025-12-31 | — | $-12.98M | $-4.09 | $-6.48M |
| Q3 '25 | 2025-09-30 | — | $-7.75M | $-2.44 | $-4.85M |
| Q2 '25 | 2025-06-30 | — | $-9.38M | $-2.96 | $-6.33M |
| Q1 '25 | 2025-03-31 | — | $-15.40M | $-4.87 | $-13.85M |
| Q4 '24 | 2024-12-31 | — | $-12.72M | $-4.00 | $-8.44M |
| Q3 '24 | 2024-09-30 | — | $-19.34M | $-6.15 | $-7.45M |
| Q2 '24 | 2024-06-30 | — | $-15.99M | $-5.09 | $-13.14M |
| Q1 '24 | 2024-03-31 | — | $-16.71M | $-6.00 | $-18.93M |
| Q4 '23 | 2023-12-31 | — | $-16.76M | $-6.00 | $-19.52M |
| Q3 '23 | 2023-09-30 | — | $-27.11M | $-9.80 | $-19.16M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-10
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.41
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-810.4%
ROA
-143.4%
Div Yield
0.00%
FCF Yield
-312.32%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$10.73M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
90.84K
SI % of Float
3.10%
Days to Cover
3.67
Short Vol Ratio
27.6%
Free Float
2.93M
Float %
91.1%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14